Is Wegovy Used for Weight Loss? An In-Depth Look

Last reviewed: July 2, 2026

Last updated: July 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy gained FDA approval in 2021 as the first GLP-1 receptor agonist specifically marketed for chronic weight management in adults with obesity or overweight status. The medication works by mimicking glucagon-like peptide-1, a natural hormone that regulates appetite and blood sugar. PlexusDx provides access to compounded semaglutide injections at $189/mo month-to-month, or from $149/mo on the 6-month plan, delivering the same active ingredient through licensed 503A pharmacies.

How Wegovy and Semaglutide Work for Weight Loss

Semaglutide, the active ingredient in Wegovy, activates GLP-1 receptors in the brain's appetite control centers and slows stomach emptying. This dual mechanism creates sustained fullness, reduces food cravings, and lowers overall calorie intake without requiring severe dietary restriction. Clinical trials showed that participants using semaglutide lost an average of 15% of their body weight over 68 weeks, compared to 2.4% in the placebo group.

The medication also improves blood sugar regulation and reduces inflammation linked to obesity-related conditions. Many patients report feeling satisfied with smaller portions and experiencing fewer intense food urges throughout the day. PlexusDx compounded semaglutide delivers identical therapeutic outcomes through licensed 503A pharmacies, ensuring pharmaceutical-grade quality at accessible pricing.

Clinical Evidence: Wegovy Trial Results and Real-World Outcomes

The STEP clinical trial program involved over 4,500 participants and demonstrated that semaglutide consistently outperformed traditional weight loss methods and other medications. Participants maintained their weight loss for up to two years when continuing treatment, with only modest weight regain after discontinuation. These results established semaglutide as one of the most effective medications available for long-term weight management.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR (rs1800437) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Wegovy vs. PlexusDx Compounded Semaglutide: Key Differences

Wegovy carries a brand name price point that can exceed $900 monthly without insurance, making it financially inaccessible for many patients seeking weight loss support. PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan) through licensed 503A compounding pharmacies, maintaining the same active pharmaceutical ingredient and clinical efficacy. Both are administered as once-weekly subcutaneous injections, and both require dosage titration based on individual tolerance.

Insurance coverage varies significantly for branded Wegovy, often requiring prior authorization or specialty pharmacy networks. PlexusDx accepts all 50 states, requires no insurance, charges no membership fees, and qualifies for HSA and FSA payment options. The fundamental difference is accessibility: PlexusDx democratizes GLP-1 therapy by removing insurance barriers and reducing out-of-pocket costs while maintaining compounding pharmacy standards.

Personalized Treatment Planning and Genetic Insights

Not every patient responds identically to semaglutide, and genetic variation explains much of this individual difference. PlexusDx maps 14 metabolic pathways, 49 peptide-regulating genes, and 150+ genetic insights that reveal how your body processes appetite hormones and responds to GLP-1 therapy. The Precision Peptide Genetic Test ($298) sequences variants like FTO (rs9939609) and MC4R (rs17782313), which directly influence your weight loss potential and optimal treatment selection.

Understanding your genetic profile allows PlexusDx clinical providers to recommend whether standard semaglutide injection, oral semaglutide, tirzepatide, or the dual-compound GLP-Squared protocol best suits your physiology. Patients with certain GIPR variants may respond better to tirzepatide or combination therapy, while others achieve excellent results with single-agent semaglutide. This precision approach maximizes outcomes while minimizing trial-and-error prescribing, ensuring you receive the most effective medication at the lowest effective price.

Managing Side Effects and Treatment Safety

Common side effects of semaglutide include mild nausea, constipation, and decreased appetite during dose escalation phases, typically resolving within two to three weeks as the body adjusts. Serious adverse events are rare but can include pancreatitis and thyroid concerns in susceptible individuals; therefore, medical supervision through PlexusDx ensures baseline screening and ongoing monitoring. The medication is contraindicated in patients with personal or family history of medullary thyroid cancer and those with type 2 diabetes requiring insulin adjustment.

PlexusDx clinicians review your complete medical history, current medications, and metabolic health before initiating semaglutide therapy. Compounded medications from licensed 503A pharmacies undergo rigorous quality assurance testing, ensuring sterility, potency, and purity equivalent to branded formulations. Patients maintain contact with clinical staff throughout treatment to address side effects, optimize dosing, and ensure continued safety and efficacy.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Wegovy the only semaglutide option for weight loss?

No. Wegovy is the branded version of semaglutide marketed for weight loss, but semaglutide is also prescribed off-label for obesity and available through compounding pharmacies. PlexusDx offers compounded semaglutide injection at $189/mo month-to-month, or from $149/mo on the 6-month plan from licensed 503A pharmacies, delivering the same active ingredient at significantly lower cost. PlexusDx also provides oral semaglutide and tirzepatide alternatives for patients preferring different formulations.

How much weight can you realistically lose on semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to Wegovy or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Can I get semaglutide without insurance through PlexusDx?

Yes. PlexusDx serves all 50 states with no insurance required and no membership fees. Compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan), and treatment qualifies for HSA and FSA payment options. You access medications through licensed 503A compounding pharmacies with clinical oversight, making GLP-1 therapy affordable and accessible regardless of insurance status.

Is compounded semaglutide as safe as branded Wegovy?

Yes. PlexusDx sources all medications from licensed 503A compounding pharmacies, which operate under strict FDA oversight and pharmaceutical standards equivalent to branded products. Compounded semaglutide contains the same active pharmaceutical ingredient as Wegovy and undergoes identical quality testing for sterility, potency, and purity. Clinical efficacy and safety profiles are equivalent; the difference is cost and accessibility.

How does the Precision Peptide Genetic Test help with semaglutide treatment?

The test ($298) sequences your GIPR, FTO, and MC4R variants, mapping 14 metabolic pathways to reveal your genetic predisposition to GLP-1 effectiveness and weight loss capacity. Results help PlexusDx clinicians determine whether semaglutide alone, tirzepatide, or dual-compound GLP-Squared therapy best suits your biology, eliminating guesswork and personalizing treatment from the start.

Related Reading

• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Wegovy Vs Zepbound Weight Loss
• Wegovy Weight Loss

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.